Tag Archives: Glen Weiss

cancer

CTCA hosts its first cancer treatments conference

Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (Western) is hosting its first ever Annual New Treatments in Oncology (ANTO) conference, focused on advances in cancer research, new treatments and patient care. The two-day ANTO event will take place on May 1-2 at the W Scottsdale hotel.

“We believe we have a unique opportunity to share with colleagues, caregivers and the general public some of the best new scientific innovations and discoveries being made every day to help our patients,” said Dr. Glen Weiss, M.D., M.B.A., who serves as a Medical Oncologist and Director of Clinical Research at CTCA® Western in Goodyear, Ariz., supervising more than 20 clinical trials involving hundreds of patients.

ANTO is designed for practicing oncologists, scientists, students, and others in the field of cancer care who are interested in cutting-edge clinical cancer developments and treatment approaches.

The weekend is structured similarly to meetings of the American Association for Cancer Research (AACR), and the American Society of Clinical Oncology (ASCO®), the nation’s two largest cancer and oncology professional organizations.

“We’ve designed this first conference as a potential national forum for cancer-care innovations, creating a space where some of the top leaders in their respective fields of research can share their knowledge, leading to a better, healthier future for all of us,” Dr. Weiss said.

Organizers hope participants will take away from ANTO: an increased knowledge of new treatments in oncology, including new methods for disease response monitoring; familiarity with the need and importance of drug development, and principles of systemic cancer therapy; and recognition of how new treatments may be incorporated into the care of cancer patients.

A scientific poster session will be held on the first day, Friday, May 1, from 10 a.m.-3 p.m. Submission of scientific abstracts for ANTO are welcome. The deadline for submitting abstract posters is April 10. More information: Preparation & Submission of Abstract Guidelines.

The second day, Saturday, May 2, is devoted to expert presentations. Among the presenters are: Dr. Robert Dreicer, University of Virginia; Dr. Ryan Corcoran, Massachusetts General Hospital; Dr. Everett Vokes, University of Chicago; Dr. Daniel Pollyea, University of Colorado; Dr. Ron Korn, Imaging Endpoints; Dr. Robert Arceci, Phoenix Children’s Hospital; Dr. Luis Diaz Jr., Johns Hopkins University; Dr. Natasha Leighl, Princess Margaret Hospital; and Dr. Weiss of CTCA.

“Staying on top of the most current developments in understanding and treating cancer is of essential importance in helping our patients receive state-of-the-art clinical trials. This is true for patients of all ages, both young and old,” said Dr. Arceci, M.D., Ph.D. “This type of gathering is a terrific way to exchange ideas about the challenges and promises for treating our patients.”

Cost of the two-day ANTO event is $150 for physicians; $50 for students and fellows; free for students, medical residents and research fellows who are first authors on accepted abstract posters.

Registration will be reimbursed upon completion of conference evaluation for all non-Arizona residents, nurses, RD, ND, and PCPs. Deadline for free registration is April 15.

Participants also will receive seven hours of Continuing Medical Education credits, approved by the Cancer Treatment Centers of America CME Committee.

The W Scottsdale, 7277 E. Camelback Road, Scottsdale, AZ, 85251, is one of Arizona’s newest high-end resorts, conveniently located in midtown Scottsdale near some of the West’s best arts, fashion and entertainment districts. Call for reservations at: 1-312-836-0100. Lunch will be provided on May 1. Breakfast and lunch will be provided May 2. Conference times both days are 10 a.m. to 4:30 p.m. (Mountain Standard Time).

research

Clinical trials change Arizona’s bioscience, business sectors

Last November, Arizona voters resoundingly passed Prop. 303 making it legal in Arizona for companies and physicians to provide terminally ill patients the “right to try” investigational drugs or therapies outside an FDA approved clinical trial.    While it sounded good in the short description provided to voters, in reality, it is unlikely to provide the outcomes one might expect since the manufacturers, physicians, pharmacists, and hospitals are required to follow the federal processes that govern these investigational treatments.  Proposition 303 did not change that.

What Are Clinical Trials?

The clinical trials process is an important step in the discovery, development and delivery pathway that leads to new life saving and live enhancing innovations.  Clinical trials are research studies that explore whether a medical strategy, treatment, or device is safe and effective for patients. These studies also may show which medical approaches work best for certain illnesses or groups of people. Clinical trials produce the best data available for health care decision making and the studies follow strict scientific standards. These standards protect patients and help produce reliable study results.

Today, in Arizona, there are 1,380 ongoing clinical trials according to ClincialTrials.gov which is the national database provided by the U.S. National Institutes of Health.  These studies cover a wide range of therapies and conditions.  Through the dedicated work of innovators, healthcare professionals, and patients, we are learning more about the safety and effectiveness of future treatments.

ClinicalTrials.gov  is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world and currently lists 187,600 studies with locations in all 50 states and in 189 countries.

How can we speed the path to innovation and give more patients access to life changing innovations?

On April 29th, members of Arizona’s life science industry and members of the community at large will gather the Sheraton Phoenix Downtown for the 2015 AZBio Expo which will focus on clinical trials in Arizona. Event details and ticket information for the 2015 AZBio Expo on April 29, 2015 at the Sheraton Phoenix Downtown are available at AZBioExpo.com.

Thanks to the support of leaders in Arizona’s life science community, practicing physicians, patients, and caregivers are invited to register for the full day conference free of charge with discount code “AZBusiness.”

The program is designed to provide an update on what Arizona’s clinical trial landscape looks like today and what is could grow to be in the future.  The program includes:

• An Introduction to The Clinical Trials Process by Mark Slater, PhD, Vice President, Research at HonorHealth Research Institute

• A keynote presentation by Matthew Huentelman, PhD, Associate Professor, Neurogenomics Division and Head of the Neurobehavioral Research Unit at the Translational Genomics Research Institute (TGen)

• A keynote presentation by Glen Weiss, MD, MBA, Director of Clinical Research & Medical Oncologist, Western Regional Medical Center, Cancer Treatment Centers of America

• A View of Arizona’s Clinical Trials Landscape by Joan Koerber-Walker, President and CEO of the Arizona Bioindustry Association and Chairman of the AdvaMed State Medical Technology Alliance in Washington, DC.

• A Discussion on Funding Clinical Trials led by Joan Koerber-Walker with Terry Urbine, PhD of the  UA College of Pharmacy, Jeremy Shefner, MD, PhD of the Barrow Neurological Institute, and Teresa Bartels from Gateway for Cancer Research.

• A Discussion on Engaging Patients in the Process led by Greg Vigdor, President & CEO, Arizona Hospital and Healthcare Association with  Brian Browne of Banner Research, Barbara Kavanaugh of the Arizona Myeloma Network, and Marcia K. Horn of the International Cancer Advocacy Network

• A Discussion on Growing Arizona’s Clinical Trials Base led by Nazneen Aziz, PhD,  Chief Research Officer and Senior Vice President, Phoenix Children’s Hospital with  Joan Rankin Shapiro, PhD of the UA College of Medicine Phoenix), and Linda Vocila, BSN, RN of TD2.

• Rapid Fire Presentations featuring Arizona companies with active clinical trials here in Arizona and around the world including:  Cancer Prevention Pharmaceuticals, Inc.,  Capstone Therapeutics,  the Center For Sustainable Health at the Biodesign Institute at Arizona State University,  Cord Blood Registry,  Insys Therapeutics, Inc., and  NuvOx Pharma.

By focusing on clinical trials together, we can help find answers for the people who matter most, the patients.

clinical research advantage - vaccines

CTCA Opening New Set of Clinical Trials

Cancer Treatment Centers of America® (CTCA) at Western Regional Medical Center (Western) in Goodyear announced it will launch 12 additional industry-sponsored clinical trials from now through December 2014. New trials will include both Phases I and II studies seeking to provide treatment options for multiple cancer types, including pancreatic, lung, prostate, colorectal and bladder.

“These research studies further our mission at CTCA® to improve overall cancer care, providing additional, innovative treatment options for our patients,” said Glen Weiss, Director of Clinical Research and Medical Oncologist, CTCA at Western.

The additional 12 trials will bring the number of open trials to 54 from 42. Patient enrollment in treatment trials has increased by more than 550 percent since the clinical research program’s inception in 2012, with Western’s clinical research team treating more than 100 patients on clinical trials involving novel treatments. This year Western exceeds the national average for adult patients participating on research studies by more than 300 percent. The breadth of research includes participation from the majority of Western’s medical oncologists who are committed to opening trials as quickly as possible.

“We truly value a patient’s immediate need for treatment options and do our best to ensure trials are fully operational in a matter of weeks versus months,” added Weiss.

For more information on the CTCA clinical trials program as well as trials currently open, visit http://www.cancercenter.com/clinical-trials/.

10258873_934794563202520_1916243681706580952_o

Az Business honors healthcare leaders

Please try entering https://graph.facebook.com/934794553202521/photos?fields=source,link,name,images,album&limit=40 into your URL bar and seeing if the page loads.

Each year, Az Business magazine hosts the Healthcare Leadership Awards to honor the women, men and institutions that bring excellence and innovation to Arizona’s healthcare system. Here are the winners and finalists who were chosen by a panel of industry experts and were recognized at the 2014 Healthcare Leadership Awards on Thursday, April 10 at the Ritz Carlton in Phoenix. See photos from the event here or on our Facebook page.

BIOSCIENCE COMPANY
Winner: Translational Genomics Research Institute (TGen)
TGen has made great strides in the field if genomics medicine. TGen researchers work to help physicians prescribe drugs that are designed more intelligently, work more effectively and have fewer toxic side effects. They have received numerous grants to support research into brain cancer and brain injuries, advanced cancers, Parkinson’s, rare childhood disorders, and more.

Finalists:
Barrow at PCH
Sonora Quest

COMMUNITY OUTREACH/EDUCATION
Winner: Barbara Kavanagh, Arizona Myeloma Network
Kavanagh’s mission is to change the lack of information and support resources for myeloma cancer by forming the Arizona Myeloma Network and the Living with Myeloma Conference, which has grown to 300 people. She also introduced the Pat and Bill Hite Cancer Caregivers Education and Support Program for caregivers to receive support and answers.

Finalists:
Catherine Ivy, Ben and Catherine Ivy Foundation
Kathleen Goeppinger, Ph.D., Midwestern University

HEALTHCARE EXECUTIVE
Winner: Robert L. Meyer, Phoenix Children’s Hospital
Meyer is credited for the rapid and significant turnaround of Phoenix Children’s Hospital from the edge of financial failure to a successful $588 million expansion that made the hospital into one of the largest pediatric medical centers in the country. PCH is ranked in U.S. News & World Report’s Best Children’s Hospitals.

Finalists:
Tim Bricker, Chandler Regional and Mercy Gilbert
Mary Lee DeCoster, Maricopa Integrated Health System
Tony Marinello, CEO of Mountain Vista, IASIS Healthcare
Ed Myers, St. Luke’s Medical Center, IASIS Healthcare

HEALTHCARE ADVOCATE
Winner: Dr. John Chen, Maricopa Integrated Health System
Serving the community’s most vulnerable residents, Chen has helped thousands of patients within the Maricopa Integrated Health System. He sees patients who are in urgent need of treatment because of their lack of dental insurance or location in third world countries. He promotes dental care and hygiene to help prevent serious diseases.

Finalists:
Dr. Randal Christensen, Crews ‘n’ Healthcare
Gerri Hether, Orchard Medical Consulting

INSURANCE PROVIDER
Winner: Blue Cross Blue Shield of Arizona
Marking its 75th anniversary in Arizona, BCBSAZ is committed to improving the quality of life for all Arizonans. The company focuses on providing the best value in health insurance as well as outside programs targeted to children and their families to help reduce childhood obesity.

Finalists:
Health Net of Arizona
UnitedHealthcare of Arizona

LEGAL ADVOCATE
Winner: Kristen Rosati, Polsinelli
As an attorney dedicated to the healthcare industry, especially to healthcare privacy, health information exchange and clinical research, Rosati has written 12 books, 30 articles and made 200 presentations on healthcare topics. She also helped establish two nonprofits in Arizona that support health information exchange and health information technology.

Finalists:
Richard Mallery, Snell and Wilmer
Martin L. Shultz, Brownstein Hyatt Farber Schreck

MEDICAL CENTER OR HOSPITAL
Winner: Scottsdale Healthcare
As a nonprofit, Scottsdale Healthcare not only employs 6,500 staff members, but also is comprised of 1,400 volunteers who donate more than 155,000 hours of service each year. They are the largest employer in the City of Scottsdale and is known for its innovative medical technology, research and patient care.

Finalists:
Banner Good Samaritan Medical Center
Cancer Treatment Centers of America
St. Joseph’s Medical Center
St. Luke’s Medical Center

MEDICAL COMPANY OF THE YEAR
Winner: Ventana
Ventana is driving personalized healthcare through the development of “companion diagnostics” to identify patients most likely to respond favorably to specific therapies. Ventana has worked is currently engaged in more that 150 collaborative projects to develop and commercialize companion diagnostics globally.

Finalists:
Medtronic
W.L. Gore and Associates

MEDICAL RESEARCH COMPANY
Winner: Banner Alzheimer’s Institute
BAI has undergone a major prevention trial to evaluate a treatment in cognitively healthy older adults at the highest known genetic risk for developing Alzheimer’s disease at older ages. The study is part of the Alzheimer’s Prevention Initiative API, an international collaboration led by BAI to accelerate the evaluation of promising but unproven prevention therapies.

Finalists:
Banner MD Anderson
University of Arizona Cancer Center

PHYSICIAN OF THE YEAR
Winner: Jimmy Chow, IASIS Healthcare
Chow improved the field of orthopedics by helping to design and teach a hybrid technique of a minimally invasive total hip replacement where the surgeon builds a new hip from inside the body. This surgery results in no post-operative limitations and many patients are discharged within 24 hours. Chow is one of 10 surgeons in the world to perform his surgery.

Finalists:
Karen Corallo Chaney, Magellan Health Services
David Notrica, Phoenix Children’s Hospital

RESEARCHER OF THE YEAR
Winner: Venkatesh G. Ramaiah, Arizona Heart Hospital
Ramaiah, the medical director and director of vascular and endovascular research, successfully created the “un balloon,” which is used to remodel thoracic endografts without the wind sock effect. This products was able to be marketed and sold.

Finalists:
David Jacofsky, CORE Institute
Glen Weiss, CTCA

LIFETIME ACHIEVEMENT
Linda Hunt, Dignity Health
Hunt, who has served as the leader of Dignity Health in Arizona since 2012, has taken a leadership role to advance healthcare and the biosciences for the people of Arizona. She has worked diligently with legislators, business leaders, educators, scientists and community organizations in order to identify, formulate, and support policies that will give Arizonans better healthcare and raise the bar of knowledge.

Facebook API came back with a faulty result. You may be accessing an album you do not have permissions to access.
Click here to see all the photos.

cancer

TGen finds clue to stop spread of lung cancer

Two cell surface receptors might be responsible for the most common form of lung cancer spreading to other parts of the body, according to a study led by the Translational Genomics Research Institute (TGen).

The hepatocyte growth factor receptor (HGFR/MET) and fibroblast growth factor-inducible 14 (FN14) are proteins associated with the potential spread of non-small cell lung cancer (NSCLC), according to the TGen study published online April 8 by the scientific journal Clinical & Experimental Metastasis.

NSCLC represents more than 85 percent of all lung cancers, which this year will kill an estimated 159,000 Americans, making it by far the leading cause of cancer-related death. It has a 5-year survival rate less than 10 percent.

The invasive and metastatic nature of NSCLC contributes to this high mortality rate, and so finding the cause of this potential to spread is key to helping patients survive.

Therapies targeting MET and FN14 are in clinical development, which could lead to treatments that could help halt or slow the spread of this lung cancer.

“As the metastatic phenotype is a major cause of lung cancer mortality, understanding and potentially targeting these pathways may reduce the high mortality rate in advanced lung cancer,” said Dr. Timothy Whitsett, an Assistant Professor in TGen’s Cancer and Cell Biology Division, and the study’s lead author.

Significantly, the TGen study found that MET and FN14 were elevated in metastatic tumors compared to primary lung tumors and suppression of MET activation or FN14 expression reduced tumor cell invasion.

“The elevation of these receptors in metastatic disease opens the possibility for therapeutic intervention,” said Dr. Nhan Tran, an Associate Professor in TGen’s Cancer and Cell Biology Division, and the study’s senior author.

Dr. Glen Weiss, Co-Unit Head of TGen’s Lung Cancer Research Laboratory and Director of Clinical Research at Cancer Treatment Centers of America at Western Regional Medical Center, said, “This study identifies some targets that already have drugs in clinical trials, and helps put them into context for what might be a rational drug development approach for the treatment of this deadly cancer.”

Other institutes that assisted with this study are: the University of Arizona; St. Joseph’s Hospital and Medical Center; and Humboldt Medical Specialists.

The study, FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion, was funded by the National Institutes of Health, and grants from the St. Joseph’s Foundation and the American Lung Association.